Shots:

• The companies will partner to promote Lyumjev (insulin lispro-aabc injection- 100 & 200 units/mL) with Dexcom G6 CGM to aid HCPs in the US for the management of diabetes- including giving visibility to the benefits of a new mealtime insulin
• HCPs treating T1D & T2D will be able to assess their patient’s glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro- helping them to manage PPG levels. The companies will enhance HCPs education by sharing information about Lyumjev & Dexcom G6 & G6 Pro via different channels
• Lyumjev is a formulation of insulin lispro- act by speeding up the absorption of insulin in the bloodstream and reduce A1C levels in adults with diabetes and has received the US FDA’s approval on Jun 15- 2020

 Ref: PRN | Image: Eli Lilly